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ABSTRACT 
 
 
 The ex vivo expansion of hematopoietic stem cells (HSCs) for transplantation has 
threefold importance: 1.) First, because of the rarity of stem cells there often isn’t a 
sufficient supply obtainable from common sources for larger children and adults. 2.) 
Secondly, patient morbidity and time to hematopoietic reconstitution following 
myeloablative preconditioning is improved by administering a larger pool of HSCs. 3.) 
Lastly, gene therapies for hematological diseases still require a robust supply of HSCs to 
offset varying degrees of inefficiency in vector mediated transfection protocols. These 
reasons, and others, have been an impetus for many discoveries made within four primary 
subdivisions within the field of HSC expansion; culture media optimization, 
hematopoietic gene regulation, development of small molecular compounds, and use of 
induced pluripotent stem cells (iPSCs). This article is a review of the current trends in 
HSC expansion methodology and posits that the majority of the singling mechanisms 
involved can be explained by the collective contribution of activating and inhibitory gene 
expression products interacting through regulatory homeostatic process mediated by HSC 
sensing of key pathway dependent thresholds.  
 
  
 v 
TABLE OF CONTENTS 
 
CHAPTER 1. INTRODUCTION .....................................................................................1 
HSC Expansion ................................................................................................................1 
Background ......................................................................................................................1 
CHAPTER 2. MODELING PATHWAY SPECIFIC THRESHOLDS ........................3 
CHAPTER 3. OPTMIZING MEDIA CONDITIONS ....................................................6 
Automated Feeding Systems ...........................................................................................6 
Recapitulating the Bone Marrow Niche: Hypoxia ..........................................................7 
CHAPTER 4. GENES AND TRANSCRIPTION FACTORS .....................................10 
Hox Genes and HSC Expansion ....................................................................................10 
Two Routes on the Wnt Pathway ..................................................................................11 
Relevancy of SALL4 .....................................................................................................12 
Relevancy of the Gatekeeper Notch ..............................................................................13 
CHAPTER 5. HSC MOLECULAR THERAPIES .......................................................16 
The Aryl Hydrocarbon Receptor Success Story ............................................................16 
Chromatin Modifying Agents: Reestablishing Multipotency ........................................17 
Culture Media Copper Chelation ...................................................................................18 
CHAPTER 6. IPSC: A POTENTIAL CURE-ALL ......................................................20 
CHAPTER 7. CONCLUSION ........................................................................................22 
LIST OF REFERENCES ................................................................................................23 
VITA..................................................................................................................................33 
 
  
 vi 
LIST OF ABBREVIATIONS 
 
 
AA2P   Ascorbic Acid 2-Phosphate 
AhR     Aryl Hydrocarbon Receptor 
APC     Adenomatous Polyposis Coli  
ARNT   Aryl Hydrocarbon Receptor Nuclear Translocator 
ATP   Adenosine-5'-Triphosphate 
bHLH    Basic-Helix-Loop-Helix 
BIO    6-Bromoindirubin-3’-Oxime 
BM    Bone Marrow 
CBF-1   C-promoter Binding Factor-1 
CDK    Cyclin-Dependant Kinase 
CDKI    Cyclin-Dependent Kinase Inhibitor 
CRUs   Competitive Repopulating Unit 
DKK1   Dickkopf-Related Protein 1 
DNA   Deoxyribonucleic Acid 
ES     Embryonic Stem 
Flt-3L   Fms-Like Tyrosine Kinase 3 
Fmi   Flamingo 
Fz   Frizzled 
GAR   Garcinol 
GSH   Glutathione 
GSK-3β  Glycogen Synthase Kinase 3 Beta 
HAT    Histone Acetyltransferase 
HDAC   Histone Deacetylase 
HIV   Human immunodeficiency virus 
HLA   Human Leukocyte Antigen 
HMPB   Human Mobilized Peripheral Blood 
HOXA10  Homeobox Protein Hox-A10 
HOXB4  Homeobox Protein Hox-B4 
HRE   Hypoxia Response Element 
HSC   Hematopoietic Stem Cell    
HSCT    Hematopoietic Stem Cell Transplant 
ICP-MS  Induction-Coupled Mass-Spectroscopy 
IL-3/6   Interleukin 3/6 
IP-10   IFN-Gamma-Inducible Protein 10 
iPSC      Induced Pluripotent Stem Cell 
ISO    Isogarcinol 
KLF4   Krueppel-Like Factor 4 
Lef     Lymphocyte-Enhancer Binding Factor 
LRP-5/6  Lipoprotein Receptor-Related Proteins 
LSK   Lin- Sca-1+ c-Kit+ 
LT-HSCs  Long-Term Hematopoietic Stem Cells 
MAPK   Mitogen-Activated Protein Kinase 
MCP-1  Monocyte Chemoattractant Protein-1 
 vii 
MIP-1α  Macrophage Inflammatory Protein 1α 
miRNA  Micro Ribonucleic Acid 
mPB    Mobilized Peripheral Blood 
MPP   Multipotent Progenitors 
mRNAs  Messenger Ribonucleic Acid 
N-cad    N-Cadherin 
NCID   Notch Intracellular Domain 
NOD   Non-Obese Diabetic Mice 
NUP98  Nuclear Pore Complex Protein 
OB   Osteoblasts  
OCT4   Octamer-Binding Transcription Factor 4 
PAS    Per-ARNT-Sim 
PBx1   Pre-B-Cell Leukemia Transcription Factor 1 
PCP   Planar Cell Polarity 
QSAR   Quantitative Structure-Activity Relationship 
ROS      Reactive Oxygen Species 
SAHA   Suberoylanilide Hydroxamic Acid 
SALL4  Sal-Like Protein 4  
SCF   Stem Cell Factor 
SCID    Severe Combined Immunodeficiency 
SOX2    Sex Determining Region Y-Box 2 
SR1    StemRegenin 
ST-HSCs  Short-Term Self-Renewing Hematopoietic Stem Cells 
TACE   Tumor Necrosis Factor Alpha Converting Enzyme 
TAT   Transactivating Protein 
TCDD   2,3,7,8-Tetrachlorodibenzo-P-Dioxin 
Tcf    T-Cell Transcription Factor 
TEPA    Tetraethylenepentamine 
TF    Transcription Factors 
TGF-β   Transforming Growth Factor Beta 
TNC    Total Nucleated Cell 
TPO   Thrombopoietin 
TSA    Trichostatin 
VPA    Valproic Acid  
5azaD    5-Aza-2’-Deoxycytidine 
5FU   Fluorouracil 
 
 1 
CHAPTER 1.    INTRODUCTION 
 
 
HSC Expansion 
 
While our knowledge of hematopoietic stem cell (HSC) regulatory systems is 
quickly becoming more advanced, the complex interplay between relevant signaling 
pathways has made development of HSC expansion regimes a challenge. Seminal 
accomplishments in overcoming HSC expansion difficulties have been achieved, albeit 
marginally, by optimizing media through the use of a multitude of cytokine combinations 
at very high doses or through the constitutive activation of key transcription factors and 
genes. While these approaches have generated invaluable knowledge about HSC 
regulatory mechanisms, they have not been overwhelmingly successful at providing 
clinically significant quantities of HSCs for use in hematopoietic stem cell transplants 
(HSCTs) without combining multiple sources. It is not lost on this author that hindsight 
affords an easy view of the shortcomings surrounding any particular method of HSC 
expansion, and that such discoveries carry great weight in our current understanding. 
However, at some point our culmination of knowledge and rapidly developing 
technology mandates that outmoded methods be challenged to quickly capture the 
possibilities that loom before us. Simply, there are numerous examples of worthwhile 
therapeutic developments that are producing markedly better HSC expansion than a half-
decade ago. It is this author’s contention that these methods should be appropriately 
integrated for maximal HSC expansion if the ultimate goal is to produce clinical quality 
stem cell treatments as quickly as possible so that patients as well as the science can 
benefit from these forward-looking strategies.   
 
 
Background 
 
Hematological disorders are routinely treated through chemotherapeutic ablation 
of the hematopoietic system and subsequent reconstitution with HSCTs. Currently, more 
than 25,000 HSCTs are performed annually utilizing HSCs from bone marrow (BM), 
umbilical cord blood (CB), and peripheral blood containing stem cells mobilized through 
granulocyte colony-stimulating factor (G-CSF) stimulation. However, matching an 
unrelated allogeneic donor with a recipient by human leukocyte antigen (HLA) can be 
challenging due to the lack of diverse race and ethnic makeup contained within many 
bone marrow registries.
1
 Even so, when a patient does meet the requirements to be 
considered for a transplant, then the need to obtain as many HSCs as possible becomes 
paramount because patient outcomes have been shown to be correlated with 
administering a total nucleated cell (TNC) dose of greater than 3 x 10
7
/kg.
2
 Moreover, 
doses attaining a TNC of 5.2 x 10
7
/kg conferred better outcomes further highlighting the 
necessity for a robust means of obtaining the greatest amount of HSCs possible.
3
  
Hematopoietic stem cell expansion for the purpose of reconstituting myeloablative 
treated patients receiving HSCTs has been an important goal for blood therapeutics since 
the pioneering work of Till and McCulloch in the 1960’s as well as Nobel laureate 
Donnall Thomas’ research on blood transplants for treating leukemia in the 1970’s.4,5 
 2 
Myeloablative preconditioning of a diseased hematopoietic system before a HSCT can 
reconstitute the space often compromises a patient’s immune system and leaves him 
anemic. Only about .01% of whole bone marrow (WBM) is thought to contain 
multipotent HSCs. There needs to be quick and robust means of reconstituting the BM 
quickly so that the duration of morbidity is reduced. Inherent limitations to supplying 
patients with sufficient numbers of HSCs are compounded by the rarity of stem cells 
within the BM space as well as the multitude of signaling pathways that carefully 
regulate their proliferation. 
 
Expanding HSCs would be inordinately easier if they were all created equal. 
Instead, HSCs are a heterogeneous mixture of cells that have been difficult to 
characterize based upon cell surface marker expression.
6
 The heterogeneity of HSCs 
within the bone marrow (BM) allows them to be divided into three main populations: 
long-term self-renewing HSCs (LT-HSCs), short-term self-renewing HSCs (ST-HSCs) 
and multipotent progenitors (MPPs). ST-HSCs and MPPs are only able to restore the 
ablated hematopoietic system of a lethally irradiated mouse for up to four months, after 
which failure of the hematopoietic system will occur. This being the case, much effort 
has been spent trying to expand and maintain LT-HSCs, which can fully restore the 
hematopoietic system of lethally irradiated BM when administered within a transplant. 
When LT-HSCs and ST-HSCs are extracted from their niche, either through G-CSF 
mobilized bone marrow or by bone marrow extraction, they can differentiate into MPPs 
through the progressive loss of self-renewal ability, which includes concordant increases 
in hematopoietic progenitor proliferation. Unless methods are in place to maintain HSC 
self-renewal capacity within specialized culturing conditions, they will undergo apoptosis 
or differentiate into progenitors, thereby jeopardizing their usefulness for conducting 
HSCTs. Current methods of promoting HSC self-renewal in favor of differentiation can 
be classified into four main categories: culturing conditions and factors (ex. hypoxia, 
automated bioreactor culture feeding, SCF, TPO, IL-3, IL-6); regulatory pathways and 
transcription factors (ex. HOXB4, Notch-1, Wnt, SALL4); small molecule therapeutics 
(ex. AhR antagonists, GSK-3β inhibitors), and through hematopoietic lineage 
commitment of induced pluripotent stem cells (iPSCs).  
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CHAPTER 2.    MODELING PATHWAY SPECIFIC THRESHOLDS 
 
 
 Many of the methods this article enumerates involve exogenous manipulations of 
the steady-state of HSC gene expression for various relevant signaling pathways.  
Granted, little detail is known about how the steady-state behaves under homeostatic 
processes for these pathways within the BM niche or how it changes under physiological 
stress. Moreover, when utilizing HSC expansion adjuvants, the interplay between genes 
that have beneficial effects on HSC expansion and the concordant increases in negative 
feedback regulatory genes can be extremely complex. Evidence of this complexity is 
documented within the literature as underwhelming HSC expansion and blocks in 
progenitor populations when constitutively expressed genes or over stimulation of 
important HSC regulatory pathways  occurs.
7–9
 Paradoxically, moderation can stray too 
far in the opposite direction, failing to achieve adequate pathway stimulation. However, 
despite this level of complexity, optimal pathway stimulation is often achieved by 
promoting key gene products whose expression enhances expansion capacity. These 
groups of genes can be described for every repeating interval of time (t) within a single 
hematopoietic stem cell through hypothetical microarray analysis, and taking repeated 
snapshots of gene expression from the moment of administering a single targeted 
adjuvant through its duration. The collective continuum of upregulated and down-
regulated genes can be placed into three broad categories for a particular point in time as: 
1.) Activating (A) genes that maintain quiescence, deter differentiation, and promote self-
renewal. 2.) Inhibitory (I) genes that serve a negative feedback role and ameliorate the 
effects of the expansion promoting set. 3.) And null (N) genes that are up or down 
regulated, but collectively and individually do not have any measurable direct or indirect 
impact on HSC expansion, and can therefore be ignored.  
 
The collective interaction between A and I determines whether a particular 
stimulus or environmental cue at a particular time will promote expansion or favor 
differentiation. While it might be useful to imagine that for every interval of time (t) each 
upregulated or down regulated gene within A could be scored on its individual ability to 
expand HSCs, but this would be of little practical use because it would ignore the 
collective interactions between complementary genes. Therefore the interaction of A with 
I over a period of time can be represented by the sum of two logarithmic curves. The 
positive A curve represents the initial stimulation events and the subsequent increase in 
gene expression that favors maintaining stem cell properties. The negative value of the I 
curve, which subtracts from the A curve, represents the delayed response of the genes 
involved in ameliorating the initial signaling wave through negative-feedback. The 
smoothed out sum of these two curves (A+ I) forms a sinusoidal biphasic response with 
potential (depending upon the signaling pathway) for repeating when the stimulation of a 
HSC pathway is strong enough to exceed the pathway specific threshold that induces 
upregulation of negative-feedback. 
 
 It is posited that stimulation that induces signaling, but does not cross the 
negative-feedback threshold range can induce expansion promoting gene expression, 
while optimally maintaining genes associated with negative-feedback at low homeostatic 
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levels. Preventing sharp biphasic swings between stimulation and feedback inhibition 
should therefore be the goal when using HSC expansion promoting adjuvants. To this 
extent automated culture feeding and dilution mechanisms can likely achieve the control 
necessary to mitigate excessive signaling crests and troughs. Examples of this reasoning 
can be observed within the Wnt and Notch pathways, which have been shown to respond 
in a biphasic manner to pathway stimulation.
10,11
 It is hypothesized that this biphasic 
response is mediated by two pathway specific thresholds. The first threshold, T1, is 
defined by the level of pathway stimulation needed to upregulate genes associated with 
negative-feedback control from a particular stimulus beyond baseline. A high T1, which 
is believed to occur in Hif-1α mediated hypoxia signaling, allows stronger environmental 
stimulation before failure occurs (Figure 1-1). Conversely, canonical Wnt signaling 
within HSCs is posited to have a low T1, mandating moderate signaling regulation to 
achieve optimal expansion. The second threshold, T2, is defined by the range that the 
collective effects of negative-feedback genes are able to reduce the expansion capabilities 
by at least 50% of optimal max signaling. T2 corresponds to the sensitivity of the pathway 
to its own negative-feedback. A low T2 will mean that a pathway needs less negative-
feedback gene expression over baseline to ameliorate expansion inducing gene 
expression. Likewise, a high T2 means that the pathway stimulation has a greater range 
and likely requires less stringent regulation. 
 
 An important factor in determining the period of the biphasic response to 
stimulation is the time between T1 being reached by A and when T2 is crossed by I. This 
period determining interval (P) along with the rate and potency of negative-feedback 
inhibition will determine the decay of the stimulation. If the amplitude of a biphasic 
response isn’t able to be compressed by adjusting the concentration of the signaling 
stimulus, so that the stimulatory signal can be maintained at a more steady level instead 
of fluctuating, then decreasing the best-fit slope of the falling wave will provide extended 
period of expansion promoting signaling. To this extent, the falling portion of the 
stimulatory wave corresponds to increasing permissiveness of HSCs to expansion 
inducing signaling. An example would be providing exogenous Notch signaling within 
HSC culture media to maintain permissiveness to concurrent canonical Wnt singling, 
which has been shown to promote expansion.
12
 By the same notion, delaying the rising 
slope of I, through the potential use of selective inhibitors or siRNA should permit a 
longer duration HSC promoting signal. 
 
 To this end, the synergistic effects of all expansion promoting genes on one 
another under the effects of a single targeted compound need to be quantitated. This 
should be done under the same stimulus for both A and I. While current technological 
limitations bar such comprehensive measurements, examples of ongoing optimization 
using induction-coupled mass spectrometry indicate potential access to comprehensive 
data across multiple singling pathways.
13
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Figure 1-1. Location of theoretical regulatory gene thresholds T1 and T2 for HIF-1 
mediated hypoxia 
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CHAPTER 3.    OPTMIZING MEDIA CONDITIONS 
 
 
 HSC cytokines have been optimized by different labs but have not worked well at 
expanding HSC cultures to the levels required for HSCT.
14–16
 While the administration of 
such cytokines is necessary for maintaining HSCs, they have not been shown to impart 
marked therapeutic potential on their own, necessitating other complimentary signals.
14
 
Despite further identification of HSC culturing media factors and a greater understanding 
of the signaling mechanisms promoting HSC expansion, none of the cytokine-based 
culturing strategies has been successful at deterring cell cycling, apoptosis, disrupted 
bone marrow homing, or HSC differentiation.
17
  
 
 
Automated Feeding Systems 
 
Advances that attempt to rectify the issues with cytokine treatments have involved 
automated culture-feeding systems. It has been known that growing HSC cultures 
produce secreted factors that, if not quenched have an overall inhibitory effect upon 
growing cultures.
18
 Recently, efforts have been made to improve ex vivo culturing 
conditions to better favor self-renewal by using automated feeding methods to limit the 
effects of inhibitory molecules (TGF-β, MCP-1, MIP-1α, MIP-1β, and IP-10) that 
accumulate within growing HSC cultures.
19–22
 By continually adding media at an 
optimized rate, an automated feeding method is reported to dilute inhibitory factors 
below a threshold so that the negative feedback effects on HSC expansion are sufficiently 
reduced. To date, this method has led to an 80-fold increase in CD34
+
 cells and an 11-
fold increase in blood stem cells, which was better than simple media exchange of the 
cultures.
23
  
 
The fed-batch method of media delivery that Csaazar et al. developed continually 
increases the volume of cultures so as to optimally expand cells and dilute away the 
inhibitory factors, which was better than perfusion driven media exchanges that maintain 
the same volume of the cultures by removing an equal amount of media that is added. 
The report claims that the fed-batch method simplifies HSC culturing conditions by 
eliminating the need for dosing the cultures with multiple compounds that independently 
target and inhibit the negative feedback ligands produced in culture. However, this 
benefit is offset by the increased complexity over basic culturing methods required with 
an automated feeding system. Moreover, the authors found that the fed-batch method 
works synergistically when combined with small molecular factors that have 
demonstrated successful HSC expansion capabilities, suggesting that the optimal means 
of expanding HSCs involves combining fed-batch with small molecular therapeutics and 
cytokines. For instance, both the small molecule aryl hydrocarbon receptor (AhR) 
antagonist StemRegenin (SR1) and the soluble TAT-HOXB4 were shown to expand 
HSCs more robustly when the inhibitory molecules were diluted away using the fed-
batch culture feeding system.
23
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Recapitulating the Bone Marrow Niche: Hypoxia 
 
 Strategies for ex vivo HSC expansion often rely on providing the essential HSC 
factors in the optimal stoichiometric ratios within the confines of a culture dish in order 
to promote robust self-renewal and survival. While efforts to understand and distill the 
multitude of intrinsic and extrinsic cues that control HSC biology have made great 
progress, determining what factors get labeled essential for ex vivo expansion can come 
down to a mixture of targeted discovery, serendipity and trial and error. So what role 
does providing hypoxic cues play in establishing an analogous physiological environment 
for HSC expansion? The answer isn’t clear; however, the importance of in vivo low 
partial pressure oxygen (pO
2
) for maintenance of HSC quiescence and reduced 
dependence upon mitochondrial oxidative phosphorylation is certain.
24
  
 
Under normal physiological conditions within the bone marrow, HSCs have been 
found to be concentrated in the less vascular endosteum regions of trabecular bone, 
regions that carry an oxygen tension between .1 to 4%.
25
 Within this hypoxic BM niche, 
HSCs have adapted to the low pO
2
 by utilizing glycolysis as the primary source of ATP 
instead of mitochondrial oxidative phosphorylation. Cellular adaption to hypoxia through 
Hif-1α-induced increases in vascular endothelial growth factor (VEGF) and Tie-1 have 
been found to play a role in maintaining HSC quiescence.
26
 There is also evidence that 
hypoxia-induced stabilization of Hif-1α plays a regulatory role within the canonical Wnt 
pathway of embryonic stem (ES) and neural stem cells that leads to β-catenin 
accumulation and downstream interaction with Lef/Tcf, which needs further investigation 
to determine if a similar function occurs within HSCs.
27
  
 
While translational processing of Hif-1α is thoroughly understood, much is still 
unknown about regulation at the transcriptional level. In 2010, Hif-1α was shown by 
Simsek et al. to be induced by Meis1, a member of the Hox gene family.
24
 Interestingly 
Meis1 was found to be expressed in 96% of LT-HSCs while only 1.4% of WBM had 
expression. Moreover,  Meis1, through a consensus binding sequence at the first intron of 
Hif-1α, plays an important role in Hif-1α preservation even in the absence of hypoxic 
cues. The ability of Meis1 to prevent Hif-1α degradation under normoxic conditions, 
along with diminishing Meis1 levels coinciding with increasing levels of HSC 
differentiation, suggests that creating a conditionally activated Meis1 could be used to 
help maintain HSC quiescence. However, there is evidence that such efforts won’t work 
or would need precise regulation because very high levels of Hif-1α expression, which a 
constitutively active Meis1 might induce, can lead to impairment of transplantation 
capacity.
9
  
 
Additional observations from Eliasson et al.
28
 were consistent with an 
independent study from Takubo et al.
9
 that found high-level expression of Hif-1α 
accomplished through either a constitutively active Hif-1α, culture treatment with HIF-
stabilizing agent FG-4497, or through deletion of the Von Hippel-Lindau (VHL) E3 that 
mediates Hif-1α degradation, ultimately led to a reduction in HSC reconstituting 
ability.
9,28,29
 This shouldn’t dissuade investigation of Meis1 for HSC expansion purposes 
because markedly different dosage-dependent outcomes exist within other HSC-relevant 
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signaling pathways (canonical Wnt, Notch-1) wherein a narrow range of stimulation 
provides optimal HSC expansion, and activation straying too far outside these cellular-
dependent ranges can lead to anemic HSC expansion or outright failure.
30
 These common 
HSC dosage-dependent sensitivities highlight the usefulness of employing a gradient of 
expression levels such as that used by Luis et al. for determining optimal HSC expansion 
ranges within the canonical Wnt pathway.
30
  
 
Concurrent with HIF induction, hypoxic HSC culturing conditions have been 
shown to be advantageous by reducing reactive oxygen species (ROS) generation and 
preventing a quiescent to cycling influx.
28,31
  Under normoxic conditions of 20% O2, 
ROS generation increases DNA damage as well as activates p38 MAPK, which is known 
to adversely affect HSC longevity.
32,33
 Hypoxic environments, such as those of the BM 
niche, have been shown to protect LT-HSCs from ROS-induced DNA damage and 
preserve LT-HSC quiescence and multilineage repopulation ability.
28
 However, it should 
not be overlooked that ROS have important signaling functions throughout the cell that 
include inducing differentiation. In line with the signaling function of ROS is the finding 
that they have been found to play a synergistic role with thrombopoietin (TPO) and other 
HSC cytokines to promote HIF-1 mediated quiescence under normoxic conditions.
34
 This 
suggests that the decision between utilizing hypoxic or normoxic culturing conditions can 
be muddled due to the complexity of interactions under differing cytokine combinations, 
which might very well obfuscate the utility for recapitulating the oxygen tension found 
within the BM niche.  
 
That being said, hypoxic conditions for ex vivo culturing have demonstrated 
increased repopulating capacity and HSC numbers, despite reductions in total cell 
numbers when contrasted with normoxic conditions.
26,28,35
 Long-term FLT3
-
 CD34
-
 Lin
-
Sca-1
+
c-Kit
+
 (LSK) cells, when cultured under hypoxic conditions, had total cell numbers 
that were significantly reduced in comparison to normoxia.
28
 However, these 
observations were shown to be due to decreases in progenitor proliferation and an efflux 
of cells from the cell cycle into G0 due in part to upregulation of cyclin-dependent kinase 
inhibitor (CDKI) genes p21cip1, p27Kip1, and p57Kip2 within the hypoxic LSK 
population. Moreover, fewer hypoxic LSK cells were required to reconstitute lethally 
irradiated mice to the same degree as normoxic cultures, suggesting that despite both 
hypoxic and normoxic conditions’ ability to preserve HSC populations; LT-HSCs are 
expanded more robustly under hypoxic conditions.  
 
While using lowered oxygen tensions instead of normal atmospheric oxygen 
levels might be of benefit, it is known that certain stem cell factors such as 
thrombopoietin (TPO) can scavenge and inactivate ROS, which most likely provides 
some of the benefits of hypoxia while maintaining the cultures under non-hypoxic 
conditions.
36
 It is hypothesized that quenching ROS formation using antioxidant culturing 
adjuvants, such as glutathione (GSH) and ascorbic acid 2-phosphate (AA2P), under 
normoxic conditions might preserve HSC multipotency and retard differentiation in 
human mobilized peripheral blood (mPB) slated for transplant.
37
 Yet to be identified is 
whether such additions will make significant improvements in HSC maintenance, and it 
is assumed that such treatments would supplement more potent forms of HSC expansion 
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instead of being used in isolation. Paradoxically, quenching ROS production within HSC 
cultures to extremely low levels could have adverse effects on expansion efforts. This is 
because findings in 2008 suggest that TPO stabilizes HIF-1α by generating mitochondrial 
ROS, that when quenched by electron transport chain (ETC) inhibitors or potent ROS 
scavengers mitigated downstream Hif-1α expression.34 Similar findings have been 
observed for proliferation-inducing cytokines such as stem cell factor (SCF), IL-3, 
erythropoietin (Epo) and granulocyte colony-stimulating factor (G-CSF), all of which 
generate and use ROS to promote proliferation.
38–40
 These are not incongruent findings, 
per se, but most likely highlight the multifunctional roles that cytokines and ROS can 
play within different cellular contexts.    
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CHAPTER 4.    GENES AND TRANSCRIPTION FACTORS 
 
 
Hox Genes and HSC Expansion 
 
Hox genes that were first implicated in embryonic development and structural 
patterning are now known to play a function not just in embryonic cells, but also in 
somatic cells, such as those of the hematopoietic system.
41
 Among the Hox genes, which 
compose the homeobox gene family, are four clusters of highly conserved transcription 
factors (TF) that are classified as A, B, C, and D and have been found to have 
overlapping roles among the clusters.
42
 Of the 39 Hox mammalian genes, 16 are 
transcribed during hematopoiesis and encode TFs that are involved in regulating self-
renewal and differentiation. Certain pivotal discoveries have shown that species of the A 
and B clusters are highly enriched in primitive hematopoietic subpopulations and play a 
positive regulatory role in HSC self-renewal.
43
  
 
HoxB4 is particularly enriched within the early hematopoietic subpopulations 
and, when overexpressed in murine bone marrow (BM) has led to a 50-fold increase in 
numbers of competitive repopulating unit (CRU). Ex vivo expansion of HoxB4-
transduced cells resulted in a 40-fold increase in HSC compared to starting numbers after 
14 days of culturing and over 1000-fold increase when compared to controls.
44
 Moreover, 
retrovirally transduced HoxB4-expanded murine HSCs maintained lymphoid and 
myeloid repopulating potential without incurring blocks in development. Successful 
efforts have been made to improve upon the retroviral transduction of HoxB4 by 
concurrently suppressing expression of Hox cofactor PBx1 as well as generating a 
NUP98 nucleoporine gene fusion with HoxB4 and HoxA10.
45
 With respect to the NUP98 
fusion proteins, there was a 300-fold increase in CRUs among the NUP98-HoxB4 
version and 2000-fold increase with the NUP98-HoxA10 version.  
 
Furthermore, strategies have been pursued that remove the need for retroviral 
transduction, such as recombinant TAT-HoxB4 fusion using the transactivating protein 
(TAT) of HIV to permit protein delivery through the cell membrane. Use of the 
transduction-free TAT-HoxB4 protein for four days on ex vivo murine HSC cultures led 
to 6-fold increases over starting HSC numbers and upwards of 20-fold increases over 
control cultures.
46
 However, problems have been reported with high ectopic expression of 
HoxB4 in human retrovirally transduced cord blood (CB) CD34
+
 cells, causing a 
presumptive block in myeloerythroid progenitor differentiation while promoting an in 
vivo growth advantage of primitive CD34
+
 populations.
47
 It has been suggested that there 
isn’t a complete block, but instead a delay in differentiation commitment that is 
potentially due to a dosage-dependent response, wherein an upper threshold, when 
crossed, increases myeloerythroid abnormalities and within an undetermined range 
optimal HSC expansion occurs without skewing production of certain progenitor 
subpopulations.
48,49
 Means of addressing the commitment delay encountered by 
constitutively high expression of HoxB4 have used inducible systems such as fusion of 
HoxB4 with tamoxifen responsive oestrogen receptor serving as a way to eliminate 
exogenous HoxB4 expression after expansion has occurred.
50
 Current studies are using 
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such systems to investigate HoxB4 target gene expression and reaction kinetics necessary 
for clinically relevant HSC expansion. 
 
 
Two Routes on the Wnt Pathway 
 
Maintenance of HSC self-renewal and inhibition of differentiation is known to 
depend upon the presence of the canonical Wnt signaling pathway, which has received 
focused research efforts.
51,52
 While there are other noncanonical Wnt pathways, namely 
the planar cell polarity (PCP) and Wnt-Ca2
+
 pathway, neither directly promotes β-catenin 
accumulation, which has been shown to play an important role in HSC self-renewal.
51
  
 
Despite the lack of direct induction of β-catenin within the noncanonical 
pathways, recent research has found that in vivo Wnt signaling through the noncanonical 
pathways maintains LT-HSC quiescence within the BM niche populated by N-cadherin 
positive osteoblasts (N-cad
+
OBs).
53
 Sugimura et al. report that N-cad
+
OBs within the BM 
microenvironment interact with HSCs expressing Flamingo (Fmi) at the N-cad
+
OB 
interface, which hydrophobically recruits the noncanonical Wnt receptor Frizzled 8 (Fz8) 
to maintain quiescence. This localized noncanonical Wnt signaling, which antagonizes 
canonical Wnt signaling, occurs predominately under homeostatic processes, but under 
physiological stress, such as when fluorouracil (5FU) is administered for myeloablative 
purposes, dynamic changes occur in the Wnt ligands of N-cad
+
OBs, leading to a shift in 
increased canonical Wnt signaling due to loss of the antagonistic actions of the 
noncanonical Wnt pathway.
53
 These observations suggest that noncanonical and 
canonical Wnt signaling within the BM microenvironment work in opposition to balance 
between HSC quiescence and proliferation.  
 
The canonical wingless-type (Wnt) pathway consists of secreted palmitoylated 
morphogens (Wnt3a) that bind the Frizzled family of receptors along with lipoprotein 
receptor-related proteins 5 and 6 (LRP-5/6) and prevent ubiquitin-driven degradation of 
β-catenin.54 Upon canonical Wnt pathway stimulation, glycogen synthase kinase (Gsk-
3β) phosphorylation of β-catenin is prevented, thereby promoting accumulation of β-
catenin, which is imported into the nucleus where it can interact with T-cell transcription 
factor (Tcf)/lymphocyte-enhancer binding factor (Lef) family to induce changes in target 
gene expression. Concomitant with a whole host of Wnt-induced gene changes are 
notable increases in HoxB4 and Notch1 expression, which have been shown to promote 
self-renewal and likely play a role in the increased self-renewal capacity of  Wnt-
stimulated HSCs.
44,55
 As of this writing, expansion through canonical Wnt stimulation 
has led to an 8-80 fold expansion in functional HSC numbers.
51
 Despite these 
achievements, apparently incongruous results within the field have made HSC expansion 
using canonical Wnt stimulation unclear.
56
  In several papers there has been 
demonstration of exhaustion and blocks in myeloid differentiation within the HSC pool 
following constitutive expression of stabilized forms of β-catenin7,57 whereas other 
reports from different labs have shown enhancement of HSC function and 
maintenance.
51,54,58
 A complete understanding of such inconsistencies will likely need 
further research; however, it does appear likely that some of the inconsistencies can be 
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attributed to differences in degree of Wnt pathway stimulation.
30
 Recent work by Luis et 
al. used five different mutations in the adenomatous polyposis coli (APC) gene to 
generate a gradient of in vivo Wnt signaling to show how intermediate levels of Wnt 
stimulation led to increased myeloid differentiation potential and clonogenicity, whereas 
only mildly increased Wnt signaling led to enhancement of HSC repopulation capacity.
30
 
Notably, higher levels of Wnt pathway activation led to total failure of repopulation 
capacity and were supported by a strong reduction of CFU colonies in methylcellulose 
assays. Reductions in HoxB4 and Cdkn1a (p21) gene expression were also observed with 
concomitant increases in Wnt stimulation, extending the evidence that optimal 
maintenance of HSC self-renewal capacity is achieved through minimal canonical Wnt 
stimulation.
30
 It is possible that low-dose Wnt stimulation may smooth out a sharp 
biphasic response and thereby may limit exaggerated expression of negative regulators 
such as Dickkopf-related protein 1 (DKK1).
52,59
 While some studies have shown 
constitutively high Wnt activation to be beneficial in HSC expansion, it now appears that 
regimented Wnt signaling offers the best HSC expansion outcomes.
51,57
  
 
Achieving optimal levels of Wnt stimulation in a dynamic system can be 
challenging; however, small molecular compounds that can be removed facilitate a level 
of control that can be very useful for ex vivo expansion. Targeting Gsk-3β, which 
functions as a hub for crosstalk among many other signaling pathways, doesn’t indicate 
precise Wnt stimulation. This is because preservation of cytoplasmic β-catenin is one of 
the primary means of changing target gene expression for the canonical Wnt, Hedgehog, 
and Notch signaling pathways.
60
 Overlap of signaling mechanisms and indirect 
regulatory feedback by downstream target genes can make it challenging to tease apart 
the exact mechanism of HSC expansion drugs.  
 
Regardless, most small molecule inhibitors of Gsk-3β attributed to the Wnt 
pathway affect the ATP binding pocket, thereby preventing phosphorylation of β-catenin 
on Thr41, Ser37, and Ser33.
61
 Several constituents of Tyrian purple, a dye produced from 
mollusks, have been successfully tested for their selective ability to inhibit Gsk-3β and 
expand the HSC pool through preventing β-catenin degradation.62  Chemical 
modifications to these compounds, in particular, 6-bromoindirubin-3’-oxime (BIO), a 
synthetic indirubin analog which is readily cell permeable, have shown a modest ability 
to promote HSC expansion and prevent loss of HSCs when grown in culture.
63
 However, 
recent insights suggest that Wnt stimulation alone isn’t sufficient to expand HSC ex vivo. 
Notch signaling appears integral to regulating HSC permissiveness to Wnt induced self-
renewal. This interdependence upon multiple signaling pathways is likely common and 
will necessitate expanding our continued understanding of HSC biology to connect once-
disparate pathways for development of better treatments. 
 
 
Relevancy of SALL4 
 
The zinc-finger transcription factor, SALL4 functions as a regulator of embryonic 
stem (ES) cell pluripotency through Oct4 and Nanog and has been recognized for its 
connections between leukemia and self-renewal in HSCs.
64
 Recent investigations of 
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SALL4 HSC expansion properties have used lentiviral transduction to constitutively 
express two isoforms (SALL4A, SALL4B) in human bone marrow (BM) CD34
+
 cells 
which produced a 130-fold expansion of the CD34
+
/CD38
-
 population after 7 days while 
cultured in cytokines (SCF, TPO, Flt-3L).
65
 Extending the culturing time to 14 days led 
to a 368-fold and 384-fold increase for SALL4A and SALL4B isoforms respectively, 
with further increases in culturing leading to over 10,000-fold expansion. However, it 
appears that SALL4 expansion is cytokine dependent and limiting levels of SCF and TPO 
impacted SALL4 HSC expansion capabilities. An effort to test a more clinically relevant 
means of using SALL4 without transducing cells led to the production of a cell-
permeable fusion SALL4B-TAT protein. When SALL4B-TAT was administered at 
200nM twice daily for four days to human CD34
+
 cells, it showed a modest 10-fold 
expansion. The authors noted that further optimization will ultimately be necessary to 
achieve more robust in vitro HSC expansion with the SALL4-TAT fusion protein. These 
future optimizations will be important because the possibility exists for the latent 
development of leukemia when transduction is used to achieve a constitutively active 
SALL4.
66
 
 
 
Relevancy of the Gatekeeper Notch 
 
The Notch signaling pathway is an evolutionary conserved mechanism involved 
in development and cell-fate specification along with regulatory functions that have been 
identified in a multitude of stem cell systems.
67
 While there are four type I receptors 
(Notch-1, -2, -3, and -4) with extracellular domains that can interact with a neighboring 
cell’s membrane-bound ligands (Delta1, -3, -4, Jagged1, -2),  determination of which 
Notch receptor-ligand interactions are most efficacious within HSCs at promoting ex vivo 
expansion is still ongoing.
11
 Mechanistically it is clear, however, that Notch receptor-
ligand interactions between HSCs and HSCs-to-stromal cells (adipocytes, endothelial 
cells, macrophages and fibroblast) within the BM niche precipitate Notch pathway 
activation. This induces TACE and γ-secretase mediated proteolytic cleavage of the 
Notch intracellular domain (NCID), freeing it to translocate into the nucleus whereupon it 
can interact with the transcription repressor CBF-1 and upregulate Notch target genes. 
Elucidation of particular target genes that have been found to have significant roles in 
maintaining HSC quiescence is still ongoing, but the Hes family of genes along with 
GATA-2 is notable.
68
  
 
Relevance of the Notch signaling pathway to hematopoietic tissues was first made 
when Milner et al.  identified Tan-1, a Notch homologue, within human Lin
-
CD34
+
 BM 
cells based upon shared consensus sequences within other Notch homologues.
69
 Notch 
activity within the hematopoietic system was further supported through the identification 
of increased reconstitution ability when soluble human Jagged-1 was administered to 
HSC cultures by Karanu et al.
70
 Furthermore, it was found that signaling between HSCs 
expressing Notch-1 and BM stromal cells expressing Jagged-1 led to inhibition of HSC 
differentiation, which was successfully abrogated through inhibition of γ-secretase 
mediated Notch activation.
71,72
 Once relevance of Notch signaling was established within 
the hematopoietic system, further investigations were conducted into HSC expansion 
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using various forms of Notch signaling, including Notch-2.
73
 Within murine models, it 
was conclusively shown that constitutively active expression of the intracellular domain 
of Notch-1 (IDN1) within HSCs resulted in cytokine-dependent immortalization that 
permitted both myeloid and lymphoid lineage differentiation.
55
 Despite moderate success 
of promoting Notch-mediated increases in HSC progenitors within murine models, 
successes within human HSCs initially proved to be hit or miss. In 2007, Chadwick et al. 
reported that when human umbilical cord blood CD34
+
 cells were transduced with a 
constitutively activated form of Notch, it led to unexpected altered cell-cycle kinetics, 
resulting in apoptotic reductions in the absolute number of CD34
+
 cells.
8
 These 
observations are in line with other reports corroborating altered cell cycle kinetics when a 
constitutively active form of Notch is used.
74
   
 
Interestingly,  no impairment of HSC self-renewal or differentiation was observed 
when a Cre-LoxP mediated conditional inactivation of Jagged1 within BM stromal cells 
was performed.
75
 These findings led Mancini et al. to conclude that Notch-1-Jagged-1 
signaling is dispensable for human HSC self-renewal and differentiation under 
physiological conditions. Further investigations will likely need to be performed to 
ascertain whether other Notch pathway paralogs with overlapping functionality 
compensated for the conditional knock out of Notch-1-Jagged-1 signaling. In light of the 
dispensable nature of certain Notch signaling pathways in vivo it is interesting to see 
marked success when an immobilized instead of soluble Delta-1 was used within 
CD34
+
CD38
-
 human cord blood cultures.
76
 Ohish et al. from the Bernstein lab 
demonstrated that an immobilized Delta-1 was able to provide upwards of 100-fold 
increase in the CD34
+ 
cell population relative to controls.
76
 This observations led to the 
publication of a 2010 phase I clinical study by Delaney et al. that successfully 
demonstrated ex vivo Notch activation can be used to increase the number of HSCs and 
progenitors while rapidly reconstituting myeloid engraftment in patients receiving 
HSCTs.
77
 This is noteworthy because studies that had previously used soluble Notch 
ligands within their investigations potentially did not induce endocytosis of the Notch 
receptor-ligand complex necessary for pathway activation.
78
 Within the same lab, a 
dosage dependent effect was observed for immobilized Delta-1 ligand stimulation of the 
Notch pathway.
79
 In that study, lower levels of immobilized Delta-1 led to increased 
CD34
+
 precursors, whereas higher levels were associated with apoptosis and inhibition of 
myeloid differentiation. Moreover, lethally irradiated NOD/SCID mice ability to 
reconstitute using CD34
+ 
cells was better when lower Delta-1 densities were used.  
 
It bears noting that these dosage-dependent Notch findings are similar to recent 
discoveries made within the canonical Wnt pathway.
30
 Within the Wnt pathway, 
relatively minimal stimulation provided better HSC expansion than higher doses did. 
While the level of stimulation is important, the bigger picture is that determining the 
optimal concentration range for HSC expansion regimens is critical. In fact, studies 
utilizing a constitutively activated Notch or Wnt, while providing important data, haven’t 
achieved ideal HSC expansion levels. 
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What would be the outcome if optimal levels of selected signaling pathways were 
determined and used simultaneously? A more advanced understanding of the complex 
interplay is finally facilitating better optimization. For instance, it has been known that 
canonical Wnt stimulation promotes self-renewal; however, it has now been found that 
Notch plays an essential gatekeeper function that controls the Wnt pathway’s ability to 
promote self-renewal.
12
 Interestingly, as Notch stimulation was inhibited, canonical Wnt 
stimulation’s self-renewal properties were diminished and led to increasing rates of 
differentiation. The integration of these two pathways fits our current understanding of 
the BM niche because increasing levels of HSC differentiation show concordant drops in 
Notch signaling. However, it is too early to determine whether differentiation itself leads 
to lowered Notch signaling or whether decreases in Notch expression precede 
differentiation events leading to the self-renewal effects of Wnt driving further 
differentiation. Regardless, this study has implications outside understanding the 
physiology of the BM niche because it can be used for better promoting the self-renewal 
properties of small molecular therapeutics, such as GSK-3β inhibitors, and further 
optimization efforts regarding optimal HSC density within starter cultures. While, it had 
been known that high starting HSC cell densities are necessary within cultures to prevent 
HSCs from prematurely differentiating, it is now assumed that high cellular densities 
provide greater HSC-to-HSC Notch signaling that maintains HSC permissiveness to 
concomitant Wnt self-renewal cures. It still remains to be seen exactly how other 
signaling pathways integrate with one another within the HSC niche, but elucidation of 
such interactions will improve upon and possibly lead to the development of new ex vivo 
expansion techniques.    
 
Furthermore, just has been observed in the Wnt pathway, Notch stimulation leads 
to the upregulation of genes that have a negative feedback regulatory roles.
80
 For the 
canonical Wnt pathway within ES cells, it was shown that a slow ramping on and off, 
biphasic response was typical.
10
 It is possible that the biphasic response described for the 
Wnt pathway might very well be truncation of a proposed oscillation model within neural 
stem cells that has yet to be applied to HSCs.
68,81
 Nonetheless, the oscillation model is 
interesting because HSCs need to function in two primary roles: self-renewal of LT-
HSCs and proliferation of progenitors. However, governing between these two roles 
during homeostasis at the cellular level is relatively slow. The cellular cycling likely 
belies a much more dynamic oscillating response that actively balances between 
homeostasis and promoting proliferation under physical duress. More detailed single-cell 
analysis will provide better insights into whether the oscillation model applies to HSCs. If 
it does, then the information gleaned from such studies will enable better control of the 
both the Notch and Wnt pathways.   
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CHAPTER 5.    HSC MOLECULAR THERAPIES 
 
 
 Development of small-molecule compounds to alter existing signaling pathways 
in order to induce HSC expansion has been of interest to researchers since the 
identification of the first HSC factors. The ability to expand stem cells with an easily 
administered adjuvant is particularly tantalizing because it can be withdrawn from the 
culture relatively easily. Moreover, challenges faced by purifying proteins and mitigating 
risks associated with vector-mediated gene integration approaches can make small-
molecule development appear tantalizing.
82
 Of course, small-molecule development has 
its own set of hurdles that can necessitate screens of large chemical libraries, which are 
often difficult or costly to access. However, advances in cheminformatics have permitted 
in silico screening of large virtual chemical libraries, which enable target genes to be 
computationally docked with databases of millions of small molecular compounds for 
reduced lead-development costs.
83
 Regardless of how they are discovered, the following 
efforts have led to chemical compounds that can induce HSC self-renewal, control 
lineage commitment of progenitors, and revert linage-committed cells back to 
multipotent states. Some of the primary means of facilitating HSC expansion include, but 
are not limited to, canonical Wnt stimulation, AhR antagonism, Notch-1 stimulation, 
chromatin modification, and copper chelation. While each of these has demonstrated its 
own measure of success at HSC expansion, StemRegenin (SR1) has come the closest so 
far of achieving the idealized goal of a single molecular compound that robustly expands 
HSCs.
84
 This does not diminish the usefulness of other molecular compounds or 
pathways, but highlights the challenge associated with finding a single compound that 
can achieve expansion in a highly regulated and complex process. 
 
 
The Aryl Hydrocarbon Receptor Success Story 
 
The aryl hydrocarbon receptor (AhR) is a basic-helix-loop-helix (bHLH) 
transcription factor that is involved in metabolizing xenobiotics and belongs to the PAS 
(Per-ARNT-Sim) superfamily, which includes genes (Hif-1α) that play a role in cellular 
sensing of hypoxia and oxidation-reduction status.
85
 The function of AhR in 
hematopoiesis is not fully understood, but it is thought that one of its roles is as a 
negative regulator of hematopoiesis by relaxing quiescence constraints and promoting 
HSC proliferation when AhR is ablated or under the influence of an antagonist.
85,86
 
Searches for endogenous AhR ligands that function to regulate hematopoiesis have not 
yielded any tangible leads; however, studies have shown that exogenous constitutive 
activation of AhR by the endocrine toxin 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
leads to a 4-fold expansion of HSC numbers, albeit with a diminished long-term 
repopulation capacity.
87
 In 2010, Boitanio et al. performed a confocal microscopy-aided 
screen of 100,000 heterocyclic compounds for changes in human mobilized peripheral 
blood (mPB) cell surface marker expression of CD34 and CD133 after ex vivo culture for 
five days.
84
 StemRegenin1 (SR1) is one of the more successful purine analogs that were 
identified to function as an antagonist of AhR, which was verified by reversibly blocking 
with TCDD. Furthermore, SR1 went on to expand primary human CD34
+
 cells 73-fold 
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after culturing with cytokines (TPO, SCF, FLT3, IL-6) for 3 weeks, which has been the 
most successful ex vivo HSC expansion method to date, save the >10,000-fold month-
long expansion reported in the Aguila et al. SALL4 study.
65,84
  
 
However, failure of the SR1 heterocycle to expand HSC in murine models 
highlights the possibility that the < 20% amino acid shared homology between mouse and 
human AhR confers species specific ligand binding.
88
 These differences between mice 
and human AhR could limit the potential of developing therapeutic leads for humans 
based on drug screens using murine models. Additionally, improvements in HSC 
expansion using AhR as a target for docking of virtual ligands cannot occur since no 
crystal structure of human AhR exists. However, there appear to be reports of successful 
use of receptor mapping or quantitative structure-activity relationship (QSAR) for lead 
development that might be applicable to in silico screens in the future if a crystal 
structure is still unavailable.
89,90
 The discovery of SR1 and its robust expansion of HSCs 
has the potential to be an effective clinical therapeutic for successful HSCTs.  
 
 
Chromatin Modifying Agents: Reestablishing Multipotency 
 
Concomitant with HSC differentiation are epigenetic changes in critical gene 
expression networks that arise from global changes in chromatin methylation and 
acetylation status.
91,92
 The hematopoietic genes that are regulated through these networks 
ultimately direct progenitor fate and restrict HSC self-renewal potential. Interest in 
reversing or mitigating changes in chromatin structure that promote differentiation so that 
HSC self-renewal capacity can be preserved has led to the use of hypomethylating agents 
as well as histone deacetylase (HDAC) and histone acetyltransferase (HAT) inhibitors. 
Of three known HDAC inhibitors including suberoylanilide hydroxamic acid (SAHA), 
trichostatin (TSA), and valproic acid (VPA), VPA has been observed to have the most 
potent epigenetic reprogramming efficiency.
93
 The antiepileptic medication VPA was 
identified as an HDAC inhibitor that can induce differentiation of cancer cells by 
promoting hyperacetylation.
94
 It has been shown that VPA functions in a dose-dependent 
manner to prevent differentiation and promote proliferation of human CD34
+
 BM cells 
when cultured for 7 days.
95
 Valproic acid induction of proliferation appears to be linked 
to down-regulation of the cyclin-dependent kinase (CDK) p21
cip-1/waf-1
, which regulates 
HSC quiescence and entry into the cell cycle.
95,96
 Additional VPA effects include 
inhibition of Gsk-3β, leading to downstream Wnt target gene expression, including 
HoxB4.
95
  
 
Additional efforts to chemically mediate epigenetic programming to facilitate 
expansion of HSCs have involved the sequential treatment of cultures with the DNA 
methyltranferase inhibitor 5-aza-2’-deoxycytidine (5azaD) followed by TSA.97 Araki et 
al. posit that the sequential nature of the treatment is necessary to remove the histone 
methylation modifications that sterically restrict access of the deacetylation inhibitor, 
TSA. The addition of the compounds to cord blood (CB) CD34
+
 cells led to a 5-fold to 
3.5-fold expansion in CD34
+ 
CD90
+
 cells that was dependent on the cocktail of cytokines 
used within the culture. However, these modest increases were not sustainable past 9 
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days of culture and corresponded with a significant decrease in p21 expression,  
suggesting that the HSC pool became exhausted.
97
  
 
Other studies on epigenetic modifiers have resulted in a screen of 92 natural 
compounds that led to the isolation of Garcinol (GAR), a plant benzophenone derivative 
from the mangosteen family Garcinia indica, which functions as a HAT inhibitor.
98
 A 
synthetic derivative of GAR, Isogarcinol (ISO) led to a 7.4-fold expansion of 
CD34
+
CD38
-
 cells when cultured with cytokines (SCF, TPO) for 7 days. Microarray 
analysis of the ISO cultured cells showed upregulation of AMICA1, BTG2, and HLF; 
however, upregulation of genes associated with HSC self-renewal (HoxB4, BMI1, 
GATA2, Notch-1) was not observed. Possible alternative mechanisms for the HSC 
expansion besides epigenetic modifications were suggested to be attributable to 
suppressed acetylation of p53 at K382, which leads to reduced targeted DNA binding by 
p53.
98,99
 Using the GAR and ISO observations as an example, it would be prudent to 
consider that other chromatin-modifying compounds could also be concurrently affecting 
post-translational modifications of proteins that play a role in HSC expansion, like p53. 
Consistent with the multiple mechanisms through which chromatin-modifying agents can 
function, further work will need to be done to understand and take advantage of their 
therapeutic possibilities.  
 
 
Culture Media Copper Chelation 
 
Copper (Cu) is a dietary trace mineral that is necessary for a fully functional 
hematopoietic system. When there is a copper deficiency the resulting effects on HSC 
differentiation can manifest in a pathology consisting of anemia, neutropenia, and 
thrombocytopenia.
100
 Efforts to understand the role that inadequate absorption of dietary 
Cu plays in hematological abnormalities have led to investigations of how Cu promotes 
HSC differentiation and whether limiting Cu availability is beneficial for therapeutic 
expansion of HSCs. There isn’t a complete understanding of the role Cu plays in HSC 
differentiation, but it is known that retinoic acid, a known promoter of differentiation, 
induces uptake of Cu during the early-stage differentiation in human myeloid leukemia 
HL-60 cells.
101
 Additionally, it has been found that cellular-free Cu in cultures promotes 
generation of reactive oxygen species (ROS), which leads to HSC exhaustion and can 
hinder maintenance of multipotent hematological pools for therapeutic purposes.
31,102
  
 
Based on these observations, investigators have successfully slowed HSC 
differentiation by attenuating copper levels using copper-specific chelators such as 
tetraethylenepentamine (TEPA).
100,102,103
  In one study, TEPA was administered to ex 
vivo cultures of purified CD34
+ 
cord blood (CB), which led to a robust enrichment of 
early progenitor subpopulations (CD34
+
CD38
-
 and CD34
+
Lin
-
) along with increased 
capacity to repopulate NOD/SCID mice.
100
  These studies set the stage for a phase I/II 
clinical trial that was established at MD Anderson Cancer Center to test the effectiveness 
of TEPA (StemEx) at expanding a single CB unit that was split into a treated and 
untreated arm, then was recombined right before patient administration.
103
 After culturing 
a portion of the CB unit with TEPA and cytokines (Flt-3 ligand, IL-6, and TPO) for 21 
 19 
days, the untreated CB arm was infused and administered within 24 hours to each of the 
respective ten patients, of whom the average age was 21. Efforts to use a single CB unit 
have historically run into the problem of not being able to provide an adult patient with 
an adequate supply of TNC for successful engraftment. In this case, the TEPA (StemEx) 
treated CB units led to an average TNC expansion of 219-fold and a 6-fold increase in 
CD34
+
 cells over starting numbers, but did not result in faster neutrophil or platelet 
reconstitution.
103
 However, even with the 219-fold expansion, the mean 1.8x10
7
/kg TNCs 
administered per adult patient fell below the 3 x 10
7
/kg dose recommended for 
engraftment, with higher levels of 5.2x10
7
/kg providing even better success.
2,3
 Despite 
the low TNC dose administered, nine of the ten patients engrafted with a 70% survival 
reported at the end of the 180-day study.
103
 At the conclusion of the StemEx clinical 
study, de Lima et al. deemed that treatment of ex vivo cultures with TEPA is feasible and 
has led to the establishment of a phase II/III study that will further address safety and 
efficacy when expanding a single CB unit for treatment of hematological cancers.  
 
Considering the modest, albeit successful, expansion that StemEx attained, it 
would be interesting to see how hypoxic conditions affect ex vivo HSC expansion since 
5% CO2 in humidified air (20% O2) was used for the respective study. Reasons for 
making such suggestions stem from evidence that administering CuCl2 can stabilize 
nuclear Hif-1α under normoxic conditions and that by chelating copper away for upwards 
of 3 weeks, while ultimately shown to benefit expansion, could be mitigating known 
benefits of  hypoxia response element (HRE) mediated gene expression.
9,104
 Whether 
additions of certain stem cell factors, such as TPO, under normoxic conditions can 
compensate for hypoxic effects would also need investigation.
105
 Regardless, it’s possible 
that TEPA-induced copper chelation could lead to decreased HIF-1 target gene 
expression and negatively impact HSC numbers. While speculative, the effects of 
hypoxia would be assumed to lead to decreases in TNC in favor of more LT-HSCs versus 
controls. While copper chelation has been shown to be a viable adjuvant to HSC 
expansion protocols, further optimizations will be needed if copper chelation is to serve 
as an alternative to more robust HSC expansion regimens, such as immobilized Delta-1 
and SR1. That being said, copper chelation is most suitable as a potential adjuvant instead 
of as a primary HSC expansion therapeutic. 
  
 20 
CHAPTER 6.    IPSC: A POTENTIAL CURE-ALL 
 
 
The seminal discovery by Taskahashi and Yamanaka that over-expression of key 
transcription factors (OCT4, SOX2, KLF4,c-MYC) in fully differentiated somatic cells 
can induce embryonic stem (ES) cell-like pluripotency by reprogramming the genomic 
methylation signature has ushered in a wave of therapeutic potential for induced 
pluripotent stem cell (iPSC) biology.
106–108
 For hematological disorders, iPSCs offer the 
possibility to produce a scalable supply of patient-derived HSCs by successfully 
recapitulating an ES-like pluripotent phenotype and inducing directed differentiation of 
progenitors.
109–111
 Recent advances reveal that reprogrammed iPSCs are amenable to 
gene-targeting strategies that can be used to treat diseases such as β-thalassemia and 
sickle cell anemia.
112–115
 However, before such methods or iPSC-based HSC expansion 
protocols can be used in a clinical setting, a number of issues will first need to be 
rectified. Foremost, factor-based reprogrammed cells do not fully recapitulate the 
epigenetic state of ES cells despite having similar (95%) global gene expression profiles 
and the ability of iPSCs to form all three germ layers: the endoderm, mesoderm, and 
ectoderm.
116,117
 Moreover, the current intractability of iPSCs to be homogenously and 
consistently reprogrammed leads to autochthonous lineage-derived methylation 
signatures that can foster differentiation that is more congruent with the tissue of 
origin.
116
  
 
Granted, more thorough reprogramming has been achieved through concomitant 
use of chromatin-modifying adjuvants such as DNA methyltransferase inhibitor 5-aza-2’-
deoxycytidine (5-AZA) and the HDAC inhibitor valproic acid.
93,116
 The drugs appear to 
ameliorate incomplete reprogramming by removing latent methylation when used in 
conjunction with current reprogramming protocols. Nonetheless, somatic nuclear transfer 
was shown to be better than iPSCs at achieving ES-cell-like properties even when treated 
with chromatin-modifying compounds. Determining what role these variable methylation 
differences play in driving differentiation of different cell types and finding ways to 
produce consistent epigenetically stable iPSCs will be imperative to future iPSC-derived 
HSC expansion.
118
  
 
There have also been concerns regarding the ability to recapitulate ES-cell-like 
telomeres, which conceivably contributed to early senescence and limited expansion of 
iPSC-derived hemangioblasts.
119
 Conversely, recent reports have shown that iPSCs have 
upregulated telomerase expression along with elongated telomeres with ES-like 
epigenetic marks.
120
 It appears that the recalcitrant nature of centromeric and telomeric 
DNA to remodeling along with observed iPSC stochastic methylation mechanisms, 
highlights the need to further understand what, if any, downstream differentiation effects 
exist.
117
 Additional iPSC concerns center on increasing reprogramming efficiency as well 
as discovering stringent clinical strategies for delivering the necessary transcription 
factors without utilizing genome-integrating vectors. While genomic safe-harbor 
locations have been identified for targeted integration for transgene expression in 
thalassemia iPSCs and it is known that exogenous transcription factors are silenced, 
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nonetheless the risk of oncogenic integration events arising should be reasonably 
mitigated for iPSC-derived HSCTs.
114
 
 
 An interesting use of synthetically modified mRNAs containing 5-methylcytidine 
for cytidine and pseudouridine in place of uridine among other structural changes has 
achieved an optimized reprogramming efficiency that surpasses .001-3% while also 
eliminating the need for vector integrations.
121
 While synthetic mRNAs presumably offer 
a reduced oncogenic profile, daily stoichiometric administration of factors can be 
prohibitively time consuming. Other non-integrating efforts have used cell-penetrating 
proteins and miRNA, but optimizations to achieve higher reprogramming efficiency are 
still necessary.
122,123
 With emerging higher-efficiency reprogramming conditions 
including hypoxia, MEK inhibitor PD0325901, GSK-3 inhibitor CHIR99021, 
kenpaullon, and the TGF-B inhibitor RepSox the possibility exists for iPSCs to be 
reprogrammed entirely by a cocktail of small molecular therapeutics.
124–126
 
 
The resounding recognition that iPSCs and the 2012 Nobel Laureates Shinya 
Yamanaka and John Gurdon have received for their respective work in 2006 and 1962 is 
clear. The potential for iPSCs to revolutionize not just HSC expansion protocols, but also 
therapeutics that will benefit from patient-tailored therapeutics is substantial. Moreover, 
the vigor with which iPSC issues are being investigated is nothing short of remarkable. It 
doesn’t take a great leap of imagination to see how progressing optimizations, along with 
our ever-increasing understanding of somatic-to-pluripotent reprogramming, is a 
keystone in a looming revolution of tailored cures for hematological diseases. Also, the 
inevitable integration of iPSCs with other successful HSC strategies will offer an exciting 
supply of clinically relevant HSC expansion opportunities.  
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CHAPTER 7.    CONCLUSION 
 
 
Insofar as multiple signaling pathways can be justifiably separated from one 
another through focused pathway research, there comes a time to unite our understanding 
of the combination of direct and indirect mechanisms that interact to produce HSC 
expansion. Although there is still much that needs to be elucidated, there is evidence that 
regulatory pathways can reinforce one another to produce better results than when 
isolation of treatments is adopted. These statements should in no way downplay the 
challenges of teasing apart complex interactions divided among multiple pathways 
because such a thorough understanding will likely necessitate HSC system-wide 
investigations to fully comprehend. However, the beginning of such efforts is under way 
with the exciting use of induction-coupled mass-spectroscopy (ICP-MS), which permits 
many cellular signatures to be analyzed simultaneously in responses to therapeutic 
modifications within a single cell.
13
 The surge in information that such advances in 
technology will provide, coupled with automated feeding systems, will facilitate precise 
control of potential negative feedback systems when expansion-promoting TFs are 
upregulated or HSC epigenetic reprogramming is desired. While still in its relative 
infancy with regard to the number of measurements that can be taken concurrently, the 
impressive amount of data that has been gathered at this early stage suggests that future 
optimizations will provide very detailed snapshots of HSC signaling under varying 
conditions.  
 
With the increasing ability to precisely identify the cellular modifications 
attributable to HSC regulatory pathways comes the key to synergizing the multitude of 
modern clinical strategies in order to expand HSCs for performing HSCTs. It is my view 
that not just through solely synergizing complementary pathways together, but also 
through a thorough gaining understanding of the indirect and direct negative feedback 
effects concordant with upregulation of key regulatory pathways, will the opportunity be 
realized to tailor a cocktail of small molecular compounds that can generate clinically 
significant quantities of HSCs. It is this author’s opinion that detailed identification of 
signaling mechanisms within HSCs will be imperative to extracting the best results 
successful for many forms of HSC expansion, as since any efforts to induce constitutive 
activation of expansion-promoting genes will likely be mitigated by a concordant 
increase in inhibitory regulatory pathways. Once these regulatory pathways are identified, 
they can be targeted through small molecular compounds which that will facilitate 
achieving the best results possible for HSCT-based therapies.  
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